Navigation Links
China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
Date:11/23/2007

n November 5, 2007, the Company entered into a new drug development contract with a third party. Pursuant to the contract, the Developer will transfer a drug patent to the Company, and also is responsible for obtaining the New Drug Certificate and the Drug Manufacturing Approval from the PRC Drug Administration Authority no later than July 1, 2009. In exchange, the Company will pay up to RMB12 million (approximately $1.6 million) to the Developer. Of the total $1.6 million, approximately $933,800 and $266,800 will need to be paid before December 31, 2007 and February 25, 2008, respectively, and the final payment ranging from $0 to $400,200, depending on the date of the Manufacturing Approval, needs to be paid no later than 10 days after the grant date of the Manufacturing Approval. Further, the two parties agreed that the Company will pay sales commission to the Developer based on the sales volume of the contracted new drug during a 10 year period after this drug is put into production. If the PRC Drug Administration Authority denies the application of the Drug Manufacturing, all payments made by the Company would be fully returned to the Company by the Developer.

Ms. Zhang Jian, continued, ''We believe that many of the distractions of the failed acquisition of Enshi are behind us. This has taken considerable management time and money away from our primary focus of building a strong pharmaceutical company in China. We now have the conditional conversion of $12.5 million of debt to equity, and believe that we will dramatically improve our cash position and have a one-time gain to income when we prevail in our Enshi litigation. We are happy to be working on new drug launches, which include an exciting new drug development agreement. We look forward to updating shareholder on these new products that we are working on to ensure our continued organic growth, as well as other potential accretive acquisition opportunities to increase our earnings and have a profitab
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
(Date:7/31/2014)... and SHENZHEN, China , July 31, ... the purchase of an Irys™System by ... BioNano,s platform to enable comprehensive exploration of human structural ... various organisms of interest, including those where no reference ... to develop new methods for multiplexing on the Irys ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Although ... of the first transcriptome-wide analyses appearing around 2008, ... assay for RNA measurement. In the last several ... more specific, work with smaller input amounts, process ... (eg, blood samples). On the bioinformatics side, there ...
(Date:7/31/2014)... 2014 The Kidney Cancer Association (KCA) has ... news magazine, Kidney Cancer News. , Bill Bro, KCA ... website maintained by an international news organization. When we began ... viewers.” , This month’s program highlights news of an enzyme ... in a recent study. Kidney Cancer News also presents a ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... , Multiporator , , , , , , , ... Protocol No. 4308 915.032 03/2000 , , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.508 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
Cached Biology Technology:BW 5147 2Brucella abortus 2Bifidobacterium animalis 2
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... release is available in German . , ... - a North African bird species with a very ... from attractive males of the same species positively affects ... highly displaying male birds in the experiment were more ...
... Institute of Standards and Technology (NIST) scientists have moved a ... blood test that can scan for thousands of disease markers ... has learned how to decode the electrical signals generated by ... artificial cell membrane. Nanopores are not new themselves; for ...
... of atherosclerosis has allowed researchers to identify a host of ... the process, before a plaque appears in the affected blood ... Blood, the journal of the American Society of Hematology. ... disturbances in the patterns of blood flow in an artery ...
Cached Biology News:Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2To predict atherosclerosis, follow the disturbed blood flow 2
... EC570-90 is a compact, lightweight, high current power ... or 2500 milliamps. It is an excellent choice ... gels. It is also ideal for all types ... be set to automatically end a run and ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
... use in Refrigerated Vapor Trap Models RVT100, ... (UVS) Models UVS400, UVS400A and UVS800DDA., A ... for use for temperatures ranging from -105 ... thermal stability and does not evaporate. Far ...
Acetate Plate Sealers 100/Box...
Biology Products: